Pfizer’s Strategic Pivot: A Long Road to Recovery
26.01.2026 - 06:53:04
Pfizer is undertaking a profound corporate transformation, divesting billions in legacy holdings to reshape its future. However, this influx of capital is shadowed by a sobering forecast from management, which does not anticipate meaningful growth resuming before 2029. For shareholders, the central question becomes whether the current dividend yield can compensate for what may be years of stagnation.
A cornerstone of this restructuring is the complete exit from ViiV Healthcare, a joint venture specializing in HIV treatments. Pfizer has agreed to sell its 11.7 percent stake to the Japanese pharmaceutical firm Shionogi. The transaction is expected to inject approximately $1.88 billion into the U.S. Read more...
@ boerse-global.de | US7170811035 PFIZER’S
